BridgeBio Pharma (BBIO) to Release Quarterly Earnings on Tuesday

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, April 29th. Analysts expect BridgeBio Pharma to post earnings of ($0.90) per share and revenue of $57.14 million for the quarter.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, analysts expect BridgeBio Pharma to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock traded down $0.06 during mid-day trading on Tuesday, reaching $35.83. 813,426 shares of the company traded hands, compared to its average volume of 2,276,577. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The firm's fifty day moving average is $33.91 and its two-hundred day moving average is $30.57. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of -12.61 and a beta of 1.08.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. Citigroup lifted their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a report on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, Scotiabank raised their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $53.00.

Insider Activity

In other BridgeBio Pharma news, CEO Neil Kumar sold 31,543 shares of BridgeBio Pharma stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the sale, the chief executive officer now owns 211,718 shares of the company's stock, valued at $7,651,488.52. The trade was a 12.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the completion of the sale, the insider now owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. This trade represents a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,374,807 shares of company stock worth $315,534,819 in the last quarter. Corporate insiders own 24.66% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.